Novel anticoagulant Xarelto filed in US
This article was originally published in Scrip
Executive Summary
Bayer HealthCare and Johnson & Johnson have filed for US approval of the novel oral once-daily anticoagulant Xarelto (rivaroxaban) for its first indication – the prevention of both deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing total hip or knee replacement surgery.